Open access · US-GOV via ClinicalTrials.gov Clinical trial

Effect of SGLT2 Inhibition on Aging-related Biomarkers in Older Obese Adults With Pre-diabetes

Authors not listed

The University of Texas Health Science Center at San Antonio · 2020

Mitochondrial dysfunction Cellular senescence Caloric restriction Human Randomized controlled trial

Abstract

Inhibitors of the sodium-glucose co-transporter (SGLT2) are FDA-approved for the treatment of type 2 diabetes (T2DM). Their mechanism of action involves lowering of blood glucose concentration secondary to increased glucose excretion of glucose by the kidney. These drugs also improve body weight, blood pressure, and cardiac function. Based on these pleiotropic effects, including its calorie restriction-mimetic properties, the study team hypothesize that SGLT2 drugs will impact several basic aging-related processes, including reductions in oxidative damage to DNA and proteins, advanced glycation end products (AGE) and receptor for AGE (RAGE), cellular senescence, and mitochondrial function.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-05-29 MST

Cite this

APA

Anonymous. (2020). Effect of SGLT2 Inhibition on Aging-related Biomarkers in Older Obese Adults With Pre-diabetes. <em>The University of Texas Health Science Center at San Antonio</em>. https://clinicaltrials.gov/study/NCT04401904

Vancouver

Anonymous. Effect of SGLT2 Inhibition on Aging-related Biomarkers in Older Obese Adults With Pre-diabetes. The University of Texas Health Science Center at San Antonio. 2020.

BibTeX

@misc{anon2020Effect, title = {Effect of SGLT2 Inhibition on Aging-related Biomarkers in Older Obese Adults With Pre-diabetes}, author = {Anonymous}, journal = {The University of Texas Health Science Center at San Antonio}, year = {2020}, }